Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Launched by FRESENIUS KABI · Apr 27, 2016
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • written informed consent
- • non-dialyzed patients with CKD
- • indication for Ketosteril according to package insert (PI), including a glomerular filtration rate (GFR) \< 25 mL/min
- • accepted supplemented protein-restricted diet and newly starting with Ketosteril (treatment naïve, i.e., never treated with Ketosteril before)
- • adult patients ≥ 18 years
- Exclusion Criteria:
- • active cancer diseases
- • pregnancy or breast feeding
- • hypersensitivity to active substances or to any of the excipients in Ketosteril
- • hypercalcaemia
- • major disorder of amino acid metabolism, e.g., hereditary diseases
- • participation in any clinical trial with an investigational drug within 30 days prior to start of study or during the study
- • illiteracy or incapability to read or write
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technology, with a strong focus on the areas of intravenous (IV) therapies, infusion devices, and clinical nutrition. With a commitment to enhancing patient care, Fresenius Kabi conducts innovative clinical trials to develop high-quality pharmaceuticals and medical devices that address unmet medical needs. The company leverages its extensive expertise in drug formulation and delivery systems to advance therapeutic solutions across various clinical indications, ensuring safety and efficacy in diverse patient populations. Through its robust research and development initiatives, Fresenius Kabi aims to contribute significantly to the healthcare landscape and improve outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials